Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William G Powderly

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2005
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40Mitchell Goldman, Gretchen A Cloud, Karen D Wade, et al.
Plos Medicine|August 26, 2022
Quantifying inequities in COVID-19 vaccine distribution over time by social vulnerability, race and ethnicity, and location: A population-level analysis in St. Louis and Kansas City, MissouriAaloke Mody, Cory Bradley, Salil Redkar, et al.
JAMA Network Open|April 25, 2024
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical TrialStephen J Balevic, Daniel K Benjamin, William G Powderly, et al.
The New England Journal of Medicine|May 16, 2008
Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler, Richard Haubrich, A Gregory DiRienzo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 6, 2010
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of americaJohn R Perfect, William E Dismukes, Francoise Dromer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2023
Persons with HIV Develop Spike-Specific Lymph Node Germinal Center Responses following SARS-CoV-2 VaccinationMichael Quinn, Luis Parra-Rodriguez, Wafaa B Alsoussi, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe DiseasePhilip A Mudd, Jeremy Chase Crawford, Jackson S Turner, et al.
Science Advances|November 14, 2020
Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine stormPhilip A Mudd, Jeremy Chase Crawford, Jackson S Turner, et al.
Open Forum Infectious Diseases|August 25, 2023
The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled TrialAngela M Reiersen, Caline Mattar, Rachel A Bender Ignacio, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2022
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19Jane A O'Halloran, Eyal Kedar, Kevin J Anstrom, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2005
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40Mitchell Goldman, Gretchen A Cloud, Karen D Wade, et al.
Plos Medicine|August 26, 2022
Quantifying inequities in COVID-19 vaccine distribution over time by social vulnerability, race and ethnicity, and location: A population-level analysis in St. Louis and Kansas City, MissouriAaloke Mody, Cory Bradley, Salil Redkar, et al.
JAMA Network Open|April 25, 2024
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical TrialStephen J Balevic, Daniel K Benjamin, William G Powderly, et al.
The New England Journal of Medicine|May 16, 2008
Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler, Richard Haubrich, A Gregory DiRienzo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 6, 2010
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of americaJohn R Perfect, William E Dismukes, Francoise Dromer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2023
Persons with HIV Develop Spike-Specific Lymph Node Germinal Center Responses following SARS-CoV-2 VaccinationMichael Quinn, Luis Parra-Rodriguez, Wafaa B Alsoussi, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe DiseasePhilip A Mudd, Jeremy Chase Crawford, Jackson S Turner, et al.
Science Advances|November 14, 2020
Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine stormPhilip A Mudd, Jeremy Chase Crawford, Jackson S Turner, et al.
Open Forum Infectious Diseases|August 25, 2023
The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled TrialAngela M Reiersen, Caline Mattar, Rachel A Bender Ignacio, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2022
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19Jane A O'Halloran, Eyal Kedar, Kevin J Anstrom, et al.
Pageof 15